WallStSmart

IDEXX Laboratories Inc (IDXX)vsENDRA Life Sciences Inc (NDRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDXX leads profitability with a 24.6% profit margin vs 0.0%. NDRA trades at a lower P/E of 0.2x. IDXX earns a higher WallStSmart Score of 61/100 (C+).

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9

NDRA

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 8.3Quality: 3.0
Piotroski: 3/9Altman Z: -38.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-40.2%)

Margin of Safety

-40.2%

Fair Value

$462.85

Current Price

$575.72

$112.87 premium

UndervaluedFair: $462.85Overvalued
NDRAUndervalued (+97.3%)

Margin of Safety

+97.3%

Fair Value

$132.74

Current Price

$3.75

$128.99 discount

UndervaluedFair: $132.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

NDRA1 strengths · Avg: 10.0/10
P/E RatioValuation
0.2x10/10

Attractively priced relative to earnings

Areas to Watch

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.972/10

Expensive relative to growth rate

P/E RatioValuation
43.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.6x2/10

Trading at 28.6x book value

NDRA4 concerns · Avg: 3.8/10
Price/BookValuation
17.0x4/10

Trading at 17.0x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.06M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : NDRA

The strongest argument for NDRA centers on P/E Ratio.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.

Bear Case : NDRA

The primary concerns for NDRA are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 3.07 is elevated, increasing financial risk.

Key Dynamics to Monitor

IDXX profiles as a mature stock while NDRA is a value play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.70 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (61/100 vs 17/100), backed by strong 24.6% margins and 14.3% revenue growth. NDRA offers better value entry with a 97.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

ENDRA Life Sciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company is headquartered in Ann Arbor, Michigan.

Visit Website →

Want to dig deeper into these stocks?